UK: Home Health Diagnostics, Microfluidics & IP

Last Updated: 10 May 2012
Article by Robin Walton

The concept of self-conducted diagnostic tests, administered by patients in their own home, would likely have been thought completely preposterous 100 years ago – conjuring-up images of an array of test-tubes, flasks and Bunsen burners. Today, however, home diagnostics (HD) are one of the fastest growing categories of what has been termed consumer-driven healthcare1. Although there are certain self-administered tests that have been used for decades, such as the home pregnancy test, consumers have been attracted to the convenience, privacy, time and cost benefits of the latest home-testing kits when compared to visiting a primary care physician. This shift has largely been driven by continued technological advances that have brought the testing means out of the lab and into small, cheaply produced, easily operated medical devices.

Traditionally, there are 3 main areas for these devices:

  1. Electronic devices (usually reusable e.g. blood pressure monitor / pulse oximeter)
  2. Chemical or Bio-marker assay devices (usually single use, e.g. urine-test paper-strips)
  3. Sample collection devices (the user collects the sample at home then sends it to a lab for testing)

Because of the falling price of simple electronic components, there are increasingly more examples of chemical or bio-marker tests which include an electronic readout such as (see Figure 1).

In terms of patents, this is a rather complex area as much of the early patented technologies covering many of the standard physical / chemical / biological assays used in these devices have long expired. Consequently, many home diagnostic-related patents tend to disclose an implementation of a standard testing method in an overall "package" which may be used/ interfaced with new technologies such as, for example, using the internet ("telemedicine") or mobile devices (known as "mHealth" – see Figure 2). The strongest patents with relevance to HDs, however, are those which claim a fundamentally new type of sensor or testing means.

New types of bodily-fluid diagnostic tests are usually first implemented clinically in the laboratory, often taking many years of technological advances for miniaturisation into a cheap home testing device – miniaturisation being desirable so only small quantities of expensive testing materials are needed. Recently, it is becoming more and more apparent that the fast-developing field known as microfluidics (MF) is going to play a key role in realising the miniaturization process more rapidly by enabling extremely small volumes of bodily fluid samples to be examined within so-called "lab-on-a-chip" miniature testing components2,3,4. IBM have created their own concept of an "ideal home diagnostic device" (see Figure 4), which incorporates a disposable "microfluidic chip". From this concept it is evident that new developments in materials, microfluidics, sensor/receptors and electronic components will be essential for the realisation of these types of devices. It is possible then, that the forthcoming high-tech, multi-component HD devices will go the way of mobile phone handsets where hundreds of patents can be associated with each device, often from many different companies under specific license agreements – this patent model for HD is in-line with the current trend towards "open innovation 5 " in the medical device sector6.

Figure 3 shows the filing timelines of both HD patents (left) and microfluidics (right). The blue lines indicate the total number of patent documents that have been published worldwide, while the red lines indicate the number of separate, unique inventions. What these graphs clearly show is that since the mid-90s there has been a steady rise in patented technology in these areas (note: the severe tail-off from 2008 onwards is an artefact due to patent documents still awaiting publication).

To investigate the HD IP, a patent dataset was collected based on the identification of patents which explicitly state that the device/method can be self-administered or is suitable for home testing – this was to exclude many diagnostic methods which can only be conducted in a laboratory. Based on these search criteria, Figure 5 (below, left) shows the top 10 patent assignees with their associated jurisdiction coverage – Japan notably being a key territory in this field.

Philips appears to dominate the IP landscape in terms of volume of patents, with a relatively equal spread across jurisdictions. Other key players are Roche, Medtronic and Panasonic. Panasonic and Toshiba's HD patent portfolios are notably weighted towards coverage in Japan, with considerably less filings in EP and US territories. Some of the key diagnostic areas in terms of the volume of patents appear to be: heart conditions, diabetes, sleep disorders, blood coagulation and cholesterol. Figure 5 (right) shows the proportion of the HD portfolios of these top 10 assignees that are focussed on these key diagnostic areas (note: some patents appear in more than one of these diagnostic categories). Patents that do not fall into these categories are often telemedicine-related or describe non-specific "health monitoring" devices where the novelty focus lies within other, non-health-related, technological attributes.

Philips, Medtronic and Cardiac Pacemakers are the key players in the heart condition field. While Roche, Abbot and Medtronic have significant proportions of their HD portfolios related to diabetes care. Home cholesterol monitoring is a smaller area in terms of IP – Roche, Abbot and Medtronic being the top 3 patent assignees. The major focus of Cordis' portfolio appears to be blood clotting related, while Roche and Siemens also have some IP in this area. Toshiba's HD patents lie outside the 5 key diagnostic areas and on further investigation they appear to be primarily telemedicine-related.

Figure 6 shows the top 10 microfluidics / lab-on-a-chip patent assignees. Unsurprisingly, there is a mix of electronic goods manufacturers and biotech / life science companies; three American universities also feature in the top 10. Caliper Life Sciences dominates this space in terms of patent numbers and is actively licensing their technologies to companies such as Aglient, Canon Life Sciences and Affymetrix 8 . Indeed, their extensive MF-related patent portfolio has been ranked as high as #2 for its technological strength in the MIT Technology Review Patent Scorecard9. The University of California and Caltech also have a large number of MF patents and are again licencing these technologies or forming spin-off start-ups with the IP – e.g. Fluidigm10 which is a MF company based upon technology licensed from Stanford University and Caltech.

In terms of jurisdiction coverage, microfluidics appears to be quite a US-driven innovation area, thus the filings have been predominantly in the US, with Japan being notably less prevalent a territory than for home diagnostic patents.

An important observation from Figure 5 & 6 is that Philips is the only company to feature in the top 10 of both HD & MF patents. Figure 7 puts their position in these areas into context with some other prominent HD / MF patent assignees. The diagram shows that Philips has a comparatively very large, evenly spread HD + MF portfolio with a 53% / 47% split of patents, respectively. This puts them in a strategically excellent position for the continued development of MF-chip-based HD devices.

Roche and Siemens also appear to be in excellent strategic positions for the development of MF-chip HD devices, with Roche slightly leaning towards HD patents at 61% HD, and Siemens slightly leaning towards MF patents at 58% MF. Assignees with extremely MF-heavy portfolios include Caliper, Geneasys, Samsung and the University of California. Whereas, Medtronic, Panasonic and Abbot have HD-heavy portfolios – the latter less so having an 85% / 15% split.

Due to the strong MF portfolios of companies such as Caliper, HD developers with virtually no MF patents, such as Panasonic, may find themselves in a situation of needing to license technologies from these MF companies should they shift their commercial focus to MF-chip HD products in the future. Indeed, Panasonic appears to be playing catch-up, having quite recently partnered with IMEC in 200811 with whom they have jointly developed various critical components of a biomedical lab-on-chip sensor12.

Patent citation analysis is a useful method to see which patents stand out and act as key reference points for forthcoming research and development. Figure 8 shows the top 10 cited patent assignees both pre-2000 (left) and post-2000 (right). The picture is quite different pre/post 2000, with Medtronic and Siemens being the only assignees to have continually high citation levels. Pre-2000, the most highly cited patent documents from these top cited assignees are all from the 1990's except one, from inventor E. Ellinwood in 1977 – "Self-powered implanted programmable medication system and method", which appears to have introduced some key concepts for implantable medication delivery devices.

Interestingly, pre-2000, Nokia have some very highly cited patent documents in the 1990's relating to diabetes monitoring equipment used in conjunction with a mobile phone – this strongly relates to the core concepts of the upcoming field of mHealth. Post-2000, Roche have a key highly cited patent application from 2004 (granted in 2010) which covers a device for sampling body fluid and a means for measuring the body fluid (e.g. porous test strips, electronic testing, optical/reflectance testing or visual inspection).

Many of the assignees with the highest post-2000 citation levels also appear in the top 10 patent assignees (Figure 5). This indicates that the new players in this area are now dominating the field in terms of patent volumes and technological significance of their patents.

Looking at the whole home diagnostics patent landscape, there is a clear split between companies developing diagnostic technologies which (a) do not require a sample of bodily fluid and (b) those that do. Companies such as Panasonic, Medtronic, Toshiba and Cardiac Pacemakers have their IP aligned with devices in category (a) and as such have not developed a microfluidics patent portfolio to date. Conversely, it is also evident that the key companies that have at least some devices in category (b), such as Siemens, Philips and Roche have developed significant microfluidics patent portfolios.

If the ideal bodily-fluid home diagnostic device (Figure 4) is to be realised, the key question is whether it will be through open innovation which is the current trend in the medical device sector, or will a powerful leader use IP to dominate the field though rigorous enforcement of their patents. The first sign of this was seen in 2007 when Roche sued Home Diagnostics Inc. for patent infringement relating to a home-testing glucometer13 – could this be a warning sign of things to come? The fact is, there are only a handful of very large corporations with the resources and the necessary volume, type and technological quality of patents to go it alone without adhering to the open innovation model.

The telemedicine and mHealth fields continue to grow in terms of products; although patents seem to feature less in these areas as the majority of embodiments to date often rely on older fundamental testing principles (e.g. Figure 2). Nevertheless, this is a rapidly expanding field with mobile phone manufacturers eager to show off innovation in this area, as demonstrated at the Mobile World Congress 201214. It is quite likely that in the future, there will be technological convergence between mHealth / telemedicine and microfluidic-chip diagnostics devices. With this convergence of products will come a whole host of IP issues – this could well become a future focus of the Smartphone / Tablet Patent Wars15.
















The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions